As litigation over GLP-1 medications continues to expand, many consumers and legal observers are asking a fundamental question: Are these lawsuits more like mass torts or class actions? To answer that, it helps to understand the key differences between these two types of legal actions — and why GLP-1 drug cases, such as those involving Ozempic, Wegovy, Trulicity, and similar medications, are generally progressing as mass tort litigation rather than traditional class action suits.
Defining Class Actions and Mass Torts
Both class actions and mass torts involve large groups of plaintiffs asserting harm caused by the same defendant or defendants. However, the legal framework and how plaintiffs’ claims are treated differ significantly.
In a class action, a representative plaintiff (or small group of representatives) sues on behalf of all similarly situated individuals. Once a class is certified, claims are handled collectively, and individual plaintiffs typically have limited control over how their cases proceed or settle.
In contrast, a mass tort allows each injured plaintiff to file an individual lawsuit. These cases are often consolidated for efficiency during pre-trial proceedings, such as discovery, while still preserving each person’s right to an individualized outcome based on their specific injuries.
“Class actions and mass torts have much in common, but their differences become critical in complex pharmaceutical litigation — where individual health impacts can vary widely even when the alleged cause is the same.” — Sarah N. Westcot, Managing Partner at Bursor & Fisher, P.A.
Why GLP-1 Lawsuits Fit the Mass Tort Model
Most GLP-1 lawsuits focus on allegations that drug manufacturers failed to adequately warn consumers and healthcare providers about serious side effects adequately. Reported injuries include gastrointestinal paralysis, intestinal obstruction, and vision-related complications. While plaintiffs may share similar legal claims, the medical outcomes differ substantially from patient to patient.
This variability makes GLP-1 cases better suited to mass tort litigation. Factors such as dosage, length of use, pre-existing conditions, and injury severity are highly individualized and require case-by-case evaluation.
“Mass torts allow each person’s unique medical circumstances to be recognized while still making the overall process more efficient for courts and litigants. In pharmaceutical cases like GLP-1, this balance is crucial.” — Dr. Nick Oberheiden, Founder at Oberheiden P.C.
Why Class Actions Are More Limited in Drug Injury Cases
Class actions work best when all class members suffer nearly identical harm caused by the same conduct. In pharmaceutical injury cases, that standard is difficult to meet. Even when the alleged failure — such as inadequate warnings — is the same, the resulting injuries can vary widely in severity, duration, and long-term impact.
Because of these differences, courts are often hesitant to certify drug injury claims as class actions. Instead, they favor litigation structures that allow individualized evidence while still addressing common legal questions efficiently.
MDLs as a Practical Middle Ground
Multidistrict litigation (MDL) has emerged as a practical solution for managing large volumes of GLP-1 lawsuits. Through an MDL, cases are centralized before a single judge for pre-trial proceedings, including discovery and expert testimony. This avoids duplicative efforts while maintaining the individuality of each claim.
Even within an MDL, bellwether trials may be used to test how juries respond to evidence and arguments. These trials can influence settlement negotiations without forcing a uniform outcome on all plaintiffs.
The Broader Impact on Consumer Litigation
The procedural path chosen for GLP-1 lawsuits reflects a broader trend in consumer health litigation. As medications reach massive audiences quickly — often driven by telehealth prescribing and online marketing — courts are increasingly tasked with balancing collective efficiency against individualized justice.
“Litigation strategies are evolving to reflect both the shared allegations and the individualized realities of consumer harm. In cases involving health products, that balance is essential to delivering fair outcomes.” — Timothy Allen, Director at Corporate Investigation Consulting.
What This Means for Consumers
For individuals harmed by GLP-1 medications, the dominance of mass tort litigation means their claims can reflect their personal medical experience, rather than being absorbed into a one-size-fits-all resolution. At the same time, consolidated proceedings help move cases forward more efficiently than thousands of isolated lawsuits.
Ultimately, GLP-1 lawsuits illustrate why mass torts — rather than class actions — remain the preferred legal framework for complex pharmaceutical injury claims in today’s legal landscape.